Indication
In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Medicine details
- Medicine name:
- selinexor (Nexpovio)
- SMC ID:
- SMC2673
- Pharmaceutical company
- Menarini Stemline
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 07 October 2024
- SMC meeting date:
- 03 September 2024
- Patient group submission deadline:
- 01 July 2024